Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28473237 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL28473349 | 0.89 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL24756015 | 0.89 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL6067844 | 0.89 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL1564372 | 0.88 | EPHX1 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| Hydrochloric Acid SCHEMBL4097350 | 0.86 | GNAI3 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL7954919 | 0.83 | — | — | |
| SCHEMBL8223865 | 0.83 | CHRM1 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL15970914 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL30185893 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188027-B | Aromatic heterocyclic derivative and application thereof in medicine | 广东东阳光药业有限公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-106496209-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-106496210-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-106518856-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6331548-B1 | PREVENTION OR TREATMENT OF CYTOKINE RELATED DISEASES | SUNTORY LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-0978516-A1 | 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY | SUNTORY LIMITED (JP) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | CHRNB2 28/4885CHRNA4 11/4885CHRNB4 34/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | CHRNB2 38/4885CHRNA4 10/4885CHRNB4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.